title: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
abstract: BACKGROUND
  Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial.
  
  
  METHODS
  Ambulatory female patients age 18 years or older with breast cancer metastatic to bone and a life expectancy of at least 3 months were eligible for the study. Bone metastases were confirmed by bone scan or bone survey within 6 months of enrollment. Sixty-one patients were treated as outpatients and were randomized to receive one of four intravenous pamidronate regimens for 12 weeks: 30 mg administered every 2 weeks, 60 mg every 4 weeks, 60 mg every 2 weeks, or 90 mg every 4 weeks. The primary efficacy parameter for this study was pain score. The change from baseline in pain score was determined for each patient at each study visit and at endpoint, defined as the last postbaseline evaluation for each patient before or at week 12. Secondary efficacy variables included narcotic scores, urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase concentrations, and bone lesion (radiologic) response.
  
  
  RESULTS
  At 3 months, the regimens of 60 mg every 4 weeks, 60 mg every 2 weeks, and 90 mg every 4 weeks resulted in significant reduction in bone pain beginning by week 6 of treatment. The regimen of 30 mg every 2 weeks was not effective. Narcotic use, as reflected by narcotic scores, did not parallel the pain scores, because there was little evidence of any effect for any of the treatment groups. Reduction in bone pain was accompanied by decreases in urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations. Side effects of pamidronate were mild and transient. Radiographic changes consistent with healing of lytic lesions were observed in 15 patients (25%).
  
  
  CONCLUSIONS
  Intravenous pamidronate is a well tolerated treatment that produced significant relief of bone pain in the majority of patients with metastatic breast cancer at the three highest doses tested.
authors.affiliation: Presbyterian University Hospital, Philadelphia, Pennsylvania.
authors.forename: D
authors.initials: D
authors.lastname: Glover
authors.forename: A
authors.initials: A
authors.lastname: Lipton
authors.forename: A
authors.initials: A
authors.lastname: Keller
authors.forename: A A
authors.initials: AA
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Browning
authors.forename: R J
authors.initials: RJ
authors.lastname: Fram
authors.forename: S
authors.initials: S
authors.lastname: George
authors.forename: K
authors.initials: K
authors.lastname: Zelenakas
authors.forename: R S
authors.initials: RS
authors.lastname: Macerata
authors.forename: J J
authors.initials: JJ
authors.lastname: Seaman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D002118:Calcium / Q000652:urine; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007262:Infusions, Intravenous; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010166:Palliative Care; D000077268:Pamidronate; D012074:Remission Induction
chemical_list: D000701:Analgesics, Opioid; D004164:Diphosphonates; D003404:Creatinine; D000077268:Pamidronate; D006909:Hydroxyproline; D002118:Calcium